The DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.
Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
Open accessAbstract
Triple-negative breast cancer (TNBC) is cancer that tested as negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein which accounts for 15%–20% of all breast cancer cases. TNBC is considered to be a poorer prognosis than other types of breast cancer, mainly because it involves more aggressive phenotypes that are similar to stem cell–like cancer cells (cancer stem cell, CSC). Thus, targeted treatment of TNBC remains a major challenge in clinical practice. This review article surveys the latest evidence concerning the role of genomic alteration in current TNBC treatment responses, current clinical trials and potential targeting sites, CSC and drug resistance, and potential strategies targeting CSCs in TNBC. Furthermore, the role of insulin-like growth factor 1 receptor (IGF-1R) and nicotinic acetylcholine receptors (nAChR) in stemness expression, chemoresistance, and metastasis in TNBC and their relevance to potential treatments are also discussed and highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
RetractedChen, C.-L., Uthaya Kumar, D. B., Punj, V., Xu, J., Sher, L., Tahara, S. M., Hess, S., & Machida, K. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.004 · Cited by 388
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 3×
“The ATP-binding cassette (ABC) transporters belong to a family of 49 membrane proteins usually related to the efflux of small molecules and compounds from the cytosol to the extracellular medium using ATP hydrolysis.”
BackgroundNishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“analyzed residual breast cancer after neoadjuvant chemotherapy and identified the additional amplification of several genes (CDK4, MCL1, JAK2, AKT1, and EGFR) and loss of mutations in BRCA1/2, ATM, and CDKN2A [30].”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Tumors can upregulate the expression of PD-1 and PD-L1, which promotes peripheral T cell exhaustion [55].”
BackgroundGlioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Identification of stem cells in small intestine and colon by marker gene Lgr5
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., et al. (2007) · Nature · doi:10.1038/nature06196 · Cited by 5,687
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · cited 1×
“In a phase III randomized trial (IMpassion 130 trial), 902 patients who had not received treatment for metastatic TNBC were randomly assigned to receive nab-paclitaxel with either atezolizumab or a placebo [59].”
MethodInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.
Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., & Mulligan, R. C. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1797 · Cited by 2,903
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
Dontu, G., Abdallah, W. M., Foley, J. M., Jackson, K. W., Clarke, M. F., Kawamura, M. J., & Wicha, M. S. (2003) · Genes & Development · doi:10.1101/gad.1061803 · Cited by 2,406
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“Through the activation of HIF-1α, the expression of EMT and stemness activators such as WNT, Hedgehog, and NOTCH pathways, as well as other stemness markers such as FOXA2, cMET, CD133, NANOG, SOX2, SOX17, and PDX1 occurs [122,123].”
BackgroundWISEMAN, H., & HALLIWELL, B. (1996) · Biochemical Journal · doi:10.1042/bj3130017 · Cited by 2,345
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Evolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 1×
“Treatment for TNBC remains a major clinical challenge due to the lack of causally proven oncogenic drivers through which to target the vast disease heterogeneity [8,23].”
BackgroundMolecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113713 · Cited by 1,464
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
IFNα activates dormant haematopoietic stem cells in vivo
Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A. (2009) · Nature · doi:10.1038/nature07815 · Cited by 1,368
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Basal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
Semenza, G. L. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104720 · Cited by 1,159
Biological subtypes of breast cancer: Prognostic and therapeutic implications
Yersal, O. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.412 · Cited by 1,156
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085 · cited 1×
“In addition, interaction between CAF and immune cells induces self-renewal properties through activation of NF-κB signaling in breast, gastric, prostate, and glioma CSCs [86].”
BackgroundPhenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
The Biology of Cancer Stem Cells
Lobo, N. A., Shimono, Y., Qian, D., & Clarke, M. F. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104154 · Cited by 1,043
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
The role of oxygen availability in embryonic development and stem cell function
Simon, M. C., & Keith, B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2354 · Cited by 967
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962 · cited 1×
“HIF-1α has long been recognized as a pivotal orchestrator of cancer cell response to hypoxic microenvironments by regulating the expression of over 60 genes involved in metabolic reprogramming and pH balance, cell proliferation/survival, apoptosis, angiogenesis, SC maintenance, matrix remodeling, metastasis, and resis…”
BackgroundHydroxylation of HIF-1: Oxygen Sensing at the Molecular Level
Semenza, G. L. (2004) · Physiology · doi:10.1152/physiol.00001.2004 · Cited by 905
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
Oskarsson, T., Acharyya, S., Zhang, X. H.-F., Vanharanta, S., Tavazoie, S. F., Morris, P. G., Downey, R. J., Manova-Todorova, K., Brogi, E., & Massagué, J. (2011) · Nature Medicine · doi:10.1038/nm.2379 · Cited by 869 · cited 1×
“Tenascin C, which is expressed in ECM, improves the efficacy of the Wnt and Notch signaling pathways, thereby stabilizing BCSCs [96].”
BackgroundIniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807 · cited 1×
“Early clinical experience with immunotherapy for TNBC also includes small studies of the single-agent anti-PD-1 antibody pembrolizumab as well as anti-PD-L1 antibodies avelumab and atezolizumab, with response rates generally lower than 20%, even in PD-L1-selected tumors [57,58].”
BackgroundExosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
Boelens, M. C., Wu, T. J., Nabet, B. Y., Xu, B., Qiu, Y., Yoon, T., Azzam, D. J., Twyman-Saint Victor, C., Wiemann, B. Z., Ishwaran, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.051 · Cited by 806
Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer
Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T. W. M., Miriyala, S., Lin, Y., Yao, J., Shi, J., Kang, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.022 · Cited by 804
Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis
Heeschen, C., Jang, J. J., Weis, M., Pathak, A., Kaji, S., Hu, R. S., Tsao, P. S., Johnson, F. L., & Cooke, J. P. (2001) · Nature Medicine · doi:10.1038/89961 · Cited by 800
Triple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Scharenberg, C. W., Harkey, M. A., & Torok-Storb, B. (2002) · Blood · doi:10.1182/blood.v99.2.507 · Cited by 770
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 680
Yu, Y., Xiao, C.-H., Tan, L.-D., Wang, Q.-S., Li, X.-Q., & Feng, Y.-M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.768 · Cited by 676
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663
Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 637
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · cited 1×
“Studies have demonstrated that CAF coculture increases the secretion of type I collagen, contributing to decreased drug uptake in breast cancer cell lines [84,85].”
BackgroundRicardo, S., Vieira, A. F., Gerhard, R., Leitão, D., Pinto, R., Cameselle-Teijeiro, J. F., Milanezi, F., Schmitt, F., & Paredes, J. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2011.090456 · Cited by 619
Kreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613
Bendall, S. C., Stewart, M. H., Menendez, P., George, D., Vijayaragavan, K., Werbowetski-Ogilvie, T., Ramos-Mejia, V., Rouleau, A., Yang, J., Bossé, M., et al. (2007) · Nature · doi:10.1038/nature06027 · Cited by 588
Dallas, N. A., Xia, L., Fan, F., Gray, M. J., Gaur, P., van Buren, G., Samuel, S., Kim, M. P., Lim, S. J., & Ellis, L. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2023 · Cited by 572
Understanding cancer stem cell heterogeneity and plasticity
Tang, D. G. (2012) · Cell Research · doi:10.1038/cr.2012.13 · Cited by 563
Physiological and pathological responses to hypoxia
Michiels, C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63747-9 · Cited by 559 · cited 1×
“HIF-1α has long been recognized as a pivotal orchestrator of cancer cell response to hypoxic microenvironments by regulating the expression of over 60 genes involved in metabolic reprogramming and pH balance, cell proliferation/survival, apoptosis, angiogenesis, SC maintenance, matrix remodeling, metastasis, and resis…”
BackgroundPDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer
Dupuy, F., Tabariès, S., Andrzejewski, S., Dong, Z., Blagih, J., Annis, M. G., Omeroglu, A., Gao, D., Leung, S., Amir, E., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.007 · Cited by 558
Buffa, F. M., Harris, A. L., West, C. M., & Miller, C. J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605450 · Cited by 556
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Drug Resistance Driven by Cancer Stem Cells and Their Niche
Prieto-Vila, M., Takahashi, R.-U., Usuba, W., Kohama, I., & Ochiya, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122574 · Cited by 508
Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H. G., Schewe, D. M., & Aguirre-Ghiso, J. A. (2013) · Nature Cell Biology · doi:10.1038/ncb2861 · Cited by 503
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Teschendorff, A. E., Miremadi, A., Pinder, S. E., Ellis, I. O., & Caldas, C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-8-r157 · Cited by 497
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Subtype and pathway specific responses to anticancer compounds in breast cancer
Heiser, L. M., Sadanandam, A., Kuo, W.-L., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018854108 · Cited by 475
ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1
Zhang, P., Wei, Y., Wang, L., Debeb, B. G., Yuan, Y., Zhang, J., Yuan, J., Wang, M., Chen, D., Sun, Y., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3013 · Cited by 454
Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells
Janiszewska, M., Suvà, M. L., Riggi, N., Houtkooper, R. H., Auwerx, J., Clément-Schatlo, V., Radovanovic, I., Rheinbay, E., Provero, P., & Stamenkovic, I. (2012) · Genes & Development · doi:10.1101/gad.188292.112 · Cited by 452
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition
Kim, N. H., Kim, H. S., Li, X.-Y., Lee, I., Choi, H.-S., Kang, S. E., Cha, S. Y., Ryu, J. K., Yoon, D., Fearon, E. R., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201103097 · Cited by 432
The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites
Gao, H., Chakraborty, G., Lee-Lim, A. P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A. H., & Giancotti, F. G. (2012) · Cell · doi:10.1016/j.cell.2012.06.035 · Cited by 430
Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence
Vera-Ramirez, L., Vodnala, S. K., Nini, R., Hunter, K. W., & Green, J. E. (2018) · Nature Communications · doi:10.1038/s41467-018-04070-6 · Cited by 430
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 428
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3599 · Cited by 427
Chen, W.-J., Ho, C.-C., Chang, Y.-L., Chen, H.-Y., Lin, C.-A., Ling, T.-Y., Yu, S.-L., Yuan, S.-S., Louisa Chen, Y.-J., Lin, C.-Y., et al. (2014) · Nature Communications · doi:10.1038/ncomms4472 · Cited by 422
Brufsky, A. M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O'Neill, V., & Rugo, H. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1255 · Cited by 421
Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment.
Bradford, G. B., Williams, B., Rossi, R., & Bertoncello, I. (1997) · PubMed · Cited by 419
for the ERIVANCE BCC Investigators, Sekulic, A., Migden, M. R., Basset-Seguin, N., Garbe, C., Gesierich, A., Lao, C. D., Miller, C., Mortier, L., Murrell, D. F., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3286-5 · Cited by 417
HDACs link the DNA damage response, processing of double-strand breaks and autophagy
Robert, T., Vanoli, F., Chiolo, I., Shubassi, G., Bernstein, K. A., Rothstein, R., Botrugno, O. A., Parazzoli, D., Oldani, A., Minucci, S., et al. (2011) · Nature · doi:10.1038/nature09803 · Cited by 412
Saxena, M., Stephens, M. A., Pathak, H., & Rangarajan, A. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.61 · Cited by 408
Yamamori, T., Yasui, H., Yamazumi, M., Wada, Y., Nakamura, Y., Nakamura, H., & Inanami, O. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.04.033 · Cited by 396
Metastatic Growth from Dormant Cells Induced by a Col-I–Enriched Fibrotic Environment
Barkan, D., El Touny, L. H., Michalowski, A. M., Smith, J. A., Chu, I., Davis, A. S., Webster, J. D., Hoover, S., Simpson, R. M., Gauldie, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2356 · Cited by 394
Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications
Nazio, F., Bordi, M., Cianfanelli, V., Locatelli, F., & Cecconi, F. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-019-0292-y · Cited by 388
Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., & Tamimi, R. M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.54 · Cited by 387
Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting
Eun, K., Ham, S. W., & Kim, H. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.3.222 · Cited by 382
Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment
Aponte, P. M., & Caicedo, A. (2017) · Stem Cells International · doi:10.1155/2017/5619472 · Cited by 375
Gong, C., Bauvy, C., Tonelli, G., Yue, W., Deloménie, C., Nicolas, V, Zhu, Y., Domergue, V, Marin-Esteban, V, Tharinger, H., et al. (2013) · Oncogene · doi:10.1038/onc.2012.252 · Cited by 369
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Drug Transporters in Drug Efficacy and Toxicity
DeGorter, M. K., Xia, C. Q., Yang, J. J., & Kim, R. B. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134529 · Cited by 359
Targeting Cancer Cell Dormancy
Recasens, A., & Munoz, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.12.004 · Cited by 356
Adaptation of Energy Metabolism in Breast Cancer Brain Metastases
Chen, E. I., Hewel, J., Krueger, J. S., Tiraby, C., Weber, M. R., Kralli, A., Becker, K., Yates, J. R., & Felding-Habermann, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3137 · Cited by 352
Burger, H., Foekens, J. A., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2003) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 341
A clinically relevant gene signature in triple negative and basal-like breast cancer
Rody, A., Karn, T., Liedtke, C., Pusztai, L., Ruckhaeberle, E., Hanker, L., Gaetje, R., Solbach, C., Ahr, A., Metzler, D., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3035 · Cited by 338
The epidemiology of triple-negative breast cancer, including race
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J. W. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9331-1 · Cited by 332
Ranganathan, A. C., Zhang, L., Adam, A. P., & Aguirre-Ghiso, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3092 · Cited by 331
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Wang, L., Leite de Oliveira, R., Huijberts, S., Bosdriesz, E., Pencheva, N., Brunen, D., Bosma, A., Song, J.-Y., Zevenhoven, J., Los-de Vries, G. T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.012 · Cited by 327
Insights into new mechanisms and models of cancer stem cell multidrug resistance
Garcia-Mayea, Y., Mir, C., Masson, F., Paciucci, R., & LLeonart, M. E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.022 · Cited by 324
Shiozawa, Y., Pedersen, E. A., Patel, L. R., Ziegler, A. M., Havens, A. M., Jung, Y., Wang, J., Zalucha, S., Loberg, R. D., Pienta, K. J., et al. (2010) · Neoplasia · doi:10.1593/neo.91384 · Cited by 314
Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction
Das, B., Tsuchida, R., Malkin, D., Koren, G., Baruchel, S., & Yeger, H. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0724 · Cited by 309
Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., Wilson, C., Merchant, M., & Settleman, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3456 · Cited by 307
Metformin: Multi-faceted protection against cancer
Del Barco, S., Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., & Menendez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 302
Fu, Y., Chang, H., Peng, X., Bai, Q., Yi, L., Zhou, Y., Zhu, J., & Mi, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102535 · Cited by 295
Modeling precision treatment of breast cancer
Daemen, A., Griffith, O. L., Heiser, L. M., Wang, N. J., Enache, O. M., Sanborn, Z., Pepin, F., Durinck, S., Korkola, J. E., Griffith, M., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-10-r110 · Cited by 295
Pastò, A., Bellio, C., Pilotto, G., Ciminale, V., Silic-Benussi, M., Guzzo, G., Rasola, A., Frasson, C., Nardo, G., Zulato, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2010 · Cited by 293
Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C. B., Roberto, M. P., Tovar, V., Sia, D., Molina-Sánchez, P., Nguyen, C. B., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312268 · Cited by 291
How I treat acute promyelocytic leukemia
Tallman, M. S., & Altman, J. K. (2009) · Blood · doi:10.1182/blood-2009-07-216457 · Cited by 284
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors
Bonde, A.-K., Tischler, V., Kumar, S., Soltermann, A., & Schwendener, R. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-35 · Cited by 283
Tamada, M., Nagano, O., Tateyama, S., Ohmura, M., Yae, T., Ishimoto, T., Sugihara, E., Onishi, N., Yamamoto, T., Yanagawa, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3024 · Cited by 275
Role of hypoxia-inducible factors in breast cancer metastasis
Gilkes, D. M., & Semenza, G. L. (2013) · Future Oncology · doi:10.2217/fon.13.92 · Cited by 274 · cited 5×
“Diagram of ongoing clinical trials in TNBCs. (A) System view of signaling pathways activated by extracellular stimuli, which triggered multiple biological functions through central hub AKT or subsequent effectors.”
BackgroundInfluentialHedgehog Signaling in the Maintenance of Cancer Stem Cells
Cochrane, C., Szczepny, A., Watkins, D., & Cain, J. (2015) · Cancers · doi:10.3390/cancers7030851 · Cited by 271
Ciavardelli, D., Rossi, C., Barcaroli, D., Volpe, S., Consalvo, A., Zucchelli, M., De Cola, A., Scavo, E., Carollo, R., D'Agostino, D., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.285 · Cited by 269
Goldman, A., Majumder, B., Dhawan, A., Ravi, S., Goldman, D., Kohandel, M., Majumder, P. K., & Sengupta, S. (2015) · Nature Communications · doi:10.1038/ncomms7139 · Cited by 260
Buccarelli, M., Marconi, M., Pacioni, S., De Pascalis, I., D’Alessandris, Q. G., Martini, M., Ascione, B., Malorni, W., Larocca, L. M., Pallini, R., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0864-7 · Cited by 257
Mitochondrial and energy metabolism‐related properties as novel indicators of lung cancer stem cells
Ye, X., Li, Q., Wang, G., Sun, F., Huang, G., Bian, X., Yu, S., & Qian, G. (2011) · International Journal of Cancer · doi:10.1002/ijc.25944 · Cited by 251
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., Weyer-Czernilofsky, U., Engle, D. D., Perez-Mancera, P. A., Coupland, S. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1201 · Cited by 243
Wnt Signaling in Cancer Stem Cell Biology
De Sousa e Melo, F., & Vermeulen, L. (2016) · Cancers · doi:10.3390/cancers8070060 · Cited by 236
Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy
Boyerinas, B., Zafrir, M., Yesilkanal, A. E., Price, T. T., Hyjek, E. M., & Sipkins, D. A. (2013) · Blood · doi:10.1182/blood-2012-12-475483 · Cited by 231
Miles, D. W., Diéras, V., Cortés, J., Duenne, A.-A., Yi, J., & O'Shaughnessy, J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt276 · Cited by 228
Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets
Clark, D. W., & Palle, K. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.11.82 · Cited by 226
Schwab, L. P., Peacock, D. L., Majumdar, D., Ingels, J. F., Jensen, L. C., Smith, K. D., Cushing, R. C., & Seagroves, T. N. (2012) · Breast Cancer Research · doi:10.1186/bcr3087 · Cited by 220
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Finn, R. S., Bengala, C., Ibrahim, N., Roché, H., Sparano, J., Strauss, L. C., Fairchild, J., Sy, O., & Goldstein, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0288 · Cited by 220
Matulonis, U. A., Wulf, G. M., Barry, W. T., Birrer, M., Westin, S. N., Farooq, S., Bell-McGuinn, K. M., Obermayer, E., Whalen, C., Spagnoletti, T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw672 · Cited by 219
Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer
Maki, R. G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5040 · Cited by 218
Selective targeting of radiation-resistant tumor-initiating cells
Zhang, M., Atkinson, R. L., & Rosen, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910179107 · Cited by 216
Wong, V. W., Yu, J., Cheng, A. S., Wong, G. L., Chan, H., Chu, E. S., Ng, E. K., Chan, F. K., Sung, J. J., & Chan, H. L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24281 · Cited by 208
Glucose metabolism in cancer cells
Annibaldi, A., & Widmann, C. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833a5577 · Cited by 196
Nicotine Promotes Tumor Growth and Metastasis in Mouse Models of Lung Cancer
Davis, R., Rizwani, W., Banerjee, S., Kovacs, M., Haura, E., Coppola, D., & Chellappan, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007524 · Cited by 193
Chemopotentiation by PARP inhibitors in cancer therapy
Tentori, L., & Graziani, G. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.010 · Cited by 192
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., Singer, C. F., Lowe, E. S., Watkins, C. L., & Carmichael, J. (2013) · Breast Cancer Research · doi:10.1186/bcr3484 · Cited by 184
Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion
Maycotte, P., Jones, K. L., Goodall, M. L., Thorburn, J., & Thorburn, A. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0487 · Cited by 181
Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy
Golden, E. B., Cho, H.-Y., Jahanian, A., Hofman, F. M., Louie, S. G., Schönthal, A. H., & Chen, T. C. (2014) · Neurosurgical Focus · doi:10.3171/2014.9.focus14504 · Cited by 179
Lee, C.-H., Huang, C.-S., Chen, C.-S., Tu, S.-H., Wang, Y.-J., Chang, Y.-J., Tam, K.-W., Wei, P.-L., Cheng, T.-C., Chu, J.-S., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq300 · Cited by 179
Self-citationMolecular mechanisms underlying tumor dormancy
Almog, N. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.004 · Cited by 178
Amir, E., Clemons, M., Purdie, C. A., Miller, N., Quinlan, P., Geddie, W., Coleman, R. E., Freedman, O. C., Jordan, L. B., & Thompson, A. M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.006 · Cited by 176
Breast cancer chemoresistance: Emerging importance of cancer stem cells
Chuthapisith, S., Eremin, J., El-Sheemey, M., & Eremin, O. (2010) · Surgical Oncology · doi:10.1016/j.suronc.2009.01.004 · Cited by 174
Martinez-Outschoorn, U. E., Goldberg, A. F., Lin, Z., Ko, Y.-H., Flomenberg, N., Wang, C., Pavlides, S., Pestell, R. G., Howell, A., Sotgia, F., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.10.17780 · Cited by 174
Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis
Wong, G. S., & Rustgi, A. K. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.592 · Cited by 172
Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1
Takahashi, R., Miyazaki, H., Takeshita, F., Yamamoto, Y., Minoura, K., Ono, M., Kodaira, M., Tamura, K., Mori, M., & Ochiya, T. (2015) · Nature Communications · doi:10.1038/ncomms8318 · Cited by 171
Wong, H. P. S., Yu, L., Lam, E. K. Y., Tai, E. K. K., Wu, W. K. K., & Cho, C. H. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.04.002 · Cited by 170
Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs
Efferth, T., Konkimalla, V. B., Wang, Y.-F., Sauerbrey, A., Meinhardt, S., Zintl, F., Mattern, J., & Volm, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4525 · Cited by 167
Song, Y.-J., Zhang, S.-S., Guo, X.-L., Sun, K., Han, Z.-P., Li, R., Zhao, Q.-D., Deng, W.-J., Xie, X.-Q., zhang, J.-W., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.021 · Cited by 164
Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.12.002 · Cited by 164
Sonnenblick, A., Agbor-Tarh, D., Bradbury, I., Di Cosimo, S., Azim, H. A., Fumagalli, D., Sarp, S., Wolff, A. C., Andersson, M., Kroep, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.7722 · Cited by 160
The cancer stem-cell signaling network and resistance to therapy
Carnero, A., Garcia‐Mayea, Y., Mir, C., Lorente, J., Rubio, I. T., & LLeonart, M. E. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.001 · Cited by 159
Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer
Schaal, C. M., Bora-Singhal, N., Kumar, D. M., & Chellappan, S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0901-2 · Cited by 158
Metabolic differences in breast cancer stem cells and differentiated progeny
Vlashi, E., Lagadec, C. H., Vergnes, L., Reue, K., Frohnen, P., Chan, M., Alhiyari, Y. M., Dratver, M. B., & Pajonk, F. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3051-2 · Cited by 157
Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation
Shi, P., Liu, W., Tala, Wang, H., Li, F., Zhang, H., Wu, Y., Kong, Y., Zhou, Z., Wang, C., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.10 · Cited by 156
Liu, L., Salnikov, A. V., Bauer, N., Aleksandrowicz, E., Labsch, S., Nwaeburu, C. C., Mattern, J., Gladkich, J., Schemmer, P., Werner, J., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28583 · Cited by 149
A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype
Wolf, J. M., Dewi, D. L., Fredebohm, J., Müller‐Decker, K., Flechtenmacher, C., Hoheisel, J. D., & Boettcher, M. (2013) · Breast Cancer Research · doi:10.1186/bcr3576 · Cited by 143
Chen, R.-J., Ho, Y., Guo, H., & Wang, Y. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn086 · Cited by 142
Self-citationAires, A., Ocampo, S. M., Simões, B. M., Rodríguez, M. J., Cadenas, J. F., Couleaud, P., Spence, K., Latorre, A., Miranda, R., Somoza, Á., et al. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/6/065103 · Cited by 142
Functional Viability Profiles of Breast Cancer
Brough, R., Frankum, J. R., Sims, D., Mackay, A. G., Mendes‐Pereira, A. M., Bajrami, I., Costa-Cabral, S., Rafiq, R., Ahmad, A. S., Cerone, M. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0107 · Cited by 140
The role of taxanes in triple-negative breast cancer: literature review
Mustacchi, G., & Laurentiis, M. D. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86105 · Cited by 139
Momi, N., Ponnusamy, M. P., Kaur, S., Rachagani, S., Kunigal, S., Chellappan, S., Ouellette, M. M., & Batra, S. K. (2012) · Oncogene · doi:10.1038/onc.2012.163 · Cited by 138
Senescence evasion by MCF-7 human breast tumor-initiating cells
Karimi‐Busheri, F., Rasouli‐Nia, A., Mackey, J. R., & Weinfeld, M. (2010) · Breast Cancer Research · doi:10.1186/bcr2583 · Cited by 137
Interferon-beta represses cancer stem cell properties in triple-negative breast cancer
Doherty, M. R., Cheon, H., Junk, D. J., Vinayak, S., Varadan, V., Telli, M. L., Ford, J. M., Stark, G. R., & Jackson, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713728114 · Cited by 136
Moreb, J. S., Muhoczy, D., Ostmark, B., & Zucali, J. R. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0233-6 · Cited by 135
Petrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., & Barni, S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2876-z · Cited by 133
Yeo, S. K., Wen, J., Chen, S., & Guan, J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2946 · Cited by 133
Litzenburger, B. C., Creighton, C. J., Tsimelzon, A. I., Chan, B. T.-Y., Hilsenbeck, S. G., Wang, T., Carboni, J. M., Gottardis, M. M., Huang, F., Chang, J. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1903 · Cited by 132
Hermann, P. C., Sancho, P., Cañamero, M., Martinelli, P., Madriles, F., Michl, P., Gress, T. M., de Pascual, R., Gandía, L., Guerra, C. E., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.002 · Cited by 130
Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance
Schmidt, F., & Efferth, T. (2016) · Pharmaceuticals · doi:10.3390/ph9020033 · Cited by 128
Zhu, H., Wang, D., Liu, Y., Su, Z., Zhang, L., Chen, F., Zhou, Y., Wu, Y., Yu, M., Zhang, Z., et al. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-119 · Cited by 127
Membrane protein-regulated networks across human cancers
Lin, C., Lee, C., Chuang, Y.-H., Lee, J.-Y., Chiu, Y.-Y., Lee, Y. W., Jong, Y., Hwang, J.-K., Huang, S., Chen, L.-C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10920-8 · Cited by 126
Self-citationTargeting Unique Metabolic Properties of Breast Tumor Initiating Cells
Feng, W., Gentles, A. J., Nair, R. V., Huang, M., Lin, Y., Lee, C. Y., Cai, S., Scheeren, F. A., Kuo, A. H., & Diehn, M. (2014) · Stem Cells · doi:10.1002/stem.1662 · Cited by 125
Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.
Duivenvoorden, W., Popović, S., Lhoták, Š., Seidlitz, E. P., Hirte, H. W., Tozer, R. G., & Singh, G. (2002) · PubMed · Cited by 124
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
Puig, I., Tenbaum, S. P., Chicote, I., Arqués, O., Martínez‐Quintanilla, J., Cuesta-Borràs, E., Ramírez, L., Gonzalo, P., Soto, A., Aguilar, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96393 · Cited by 123
Mamaeva, V., Niemi, R., Beck, M., Özliseli, E., Desai, D., Landor, S. K.-J., Grönroos, T. J., Kronqvist, P., Pettersen, I. K. N., McCormack, E., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.42 · Cited by 120
Metadata
- Authors
- Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-09-09
- Volume
- 11
- Issue
- 9
- Pages
- 1334
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2972270957
- Cited by
- 260
- References
- 271
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.